|
|||||
|
|
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial |
|
| Authors: | Hu Ke Wang Mengmei Zhao Yang Zhang Yunting Wang Tao Zheng Zhishui Li Xiaochen Zeng Shaolin Zhao Dong Li Honglin Xu Ke Lan Ke |
| Institution: | 1.Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China2.Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China3.State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China4.Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430072, China |
| Abstract: | Virologica Sinica - We recently reported that inhibitors against human dihydroorotate dehydrogenase (DHODH) have broad-spectrum antiviral activities including their inhibitory efficacies on... |
| Keywords: | DHODH inhibitors Leflunomide Coronavirus disease 2019 (COVID-19) Viral shedding time Inflammation |
| 本文献已被 SpringerLink 等数据库收录！ | |
| 点击此处可从《中国病毒学》浏览原始摘要信息 | |
| 点击此处可从《中国病毒学》下载免费的PDF全文 | |